AAV Formulation Stabilization at -20 C
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Adeno-associated virus (AAV) biotherapeutics require stringent cold storage at −80° C, which is impractical for global distribution due to logistical challenges and variability in freezer temperatures, leading to instability and potential degradation, especially during thawing and storage at higher temperatures like −20° C.
Innovation Solution
A pharmaceutical composition comprising recombinant AAV, buffering agents, ionic salts, sucrose, and surfactants like poloxamer 188, which maintains pH stability between 6 and 9 and prevents crystallization, ensuring stability at various temperature conditions, including refrigerated and frozen states.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AAV is stored at −80° C. to maintain stability, then product degradation is prevented, but supply chain complexity and distribution difficulty increase
Solution Approach 1:
The patent modifies the physical-chemical parameters of the storage system by introducing sucrose as a cryoprotectant and buffering agents to stabilize pH. These parameter changes enable the AAV formulation to maintain stability at higher temperatures (−20° C. to 4° C.) rather than requiring ultra-low temperature storage at −80° C., thereby reducing infrastructure complexity while preserving product reliability
Solution Approach 2:
Sucrose acts as an intermediary substance that mediates between the AAV particles and the freezing environment. The sucrose forms a protective matrix during freezing that prevents ice crystal formation and excipient concentration, thereby protecting the AAV from degradation without requiring extreme cold storage conditions
2Ease of operation
If AAV is stored at higher frozen temperatures (−20° C.) to simplify distribution, then logistics ease improves, but product stability and purity deteriorate due to crystallization and pH shifts
Solution Approach 1:
The patent applies beforehand cushioning by incorporating sucrose and buffering agents into the formulation before storage. The sucrose concentration (5-20% w/v) is specifically designed to prevent crystallization and excipient concentration during freezing, while the buffering agents (phosphate, citrate, or acetate buffers at pH 6.0-8.0) preemptively maintain pH stability, cushioning the AAV against degradation during storage at −20° C.
3Reliability
If traditional buffer formulations are used at −80° C., then product stability is maintained, but excipient concentration and phase separation occur during freezing
Solution Approach 1:
The patent changes the concentration parameter of sucrose to 5-20% w/v, which is sufficiently high to prevent crystallization and excipient concentration during freezing. This parameter change fundamentally alters the freezing behavior of the formulation, preventing phase separation and maintaining composition uniformity while preserving product stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition significantly enhances the stability and infectivity of AAV, allowing for extended storage and distribution at −20° C, maintaining potency and reducing aggregation, even after multiple freeze-thaw cycles, thus overcoming the limitations of traditional cold storage requirements.
Implementation Method 1
Sucrose is provided at a concentration that prevents crystallization of the composition
Implementation Method 2
buffering agent, ionic salt, sucrose, and surfactant such as poloxamer 188. Sucrose is provided at a concentration that prevents crystallization of the composition and maintains a pH between 6 and 9 during frozen and liquid states
Data Source
AI summary
Provided herein are pharmaceutical compositions comprising a recombinant adeno-associated virus (AAV), salt excipient or buffer agent, sugar and surfactant. Also provided herein are methods for treating or preventing a disease in a subject by administering a therapeutically effective amount of the said pharmaceutical composition to the subject in need.